| Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Q Deng, G Han, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen, E Dai, ... Nature medicine 26 (12), 1878-1887, 2020 | 367 | 2020 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... Cancer discovery 7 (10), 1088-1097, 2017 | 178 | 2017 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 168 | 2020 |
| Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ... Journal of Thoracic Oncology 15 (9), 1449-1459, 2020 | 130 | 2020 |
| Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma X Hu, J Fujimoto, L Ying, J Fukuoka, K Ashizawa, W Sun, A Reuben, ... Nature communications 10 (1), 2978, 2019 | 104 | 2019 |
| Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features H Dejima, X Hu, R Chen, J Zhang, J Fujimoto, ER Parra, C Haymaker, ... Nature communications 12 (1), 2722, 2021 | 85 | 2021 |
| The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma M Zhuo, Y Guan, X Yang, L Hong, Y Wang, Z Li, R Chen, HA Abbas, ... Clinical Cancer Research 26 (4), 892-901, 2020 | 83 | 2020 |
| Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target X Le, MV Negrao, A Reuben, L Federico, L Diao, D McGrail, M Nilsson, ... Journal of thoracic oncology 16 (4), 583-600, 2021 | 72 | 2021 |
| The role of dasatinib in the management of chronic myeloid leukemia R Chen, B Chen Drug design, development and therapy, 773-779, 2015 | 72 | 2015 |
| Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) Y Li, Z Zhang, Y Hu, X Yan, Q Song, G Wang, R Chen, S Jiao, J Wang Frontiers in Oncology 10, 654, 2020 | 68 | 2020 |
| Siltuximab (CNTO 328): a promising option for human malignancies R Chen, B Chen Drug design, development and therapy, 3455-3458, 2015 | 62 | 2015 |
| Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD H Zhang, R Chen, J Cheng, N Jin, B Chen Patient preference and adherence, 105-111, 2015 | 45 | 2015 |
| Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas X Hu, MR Estecio, R Chen, A Reuben, L Wang, J Fujimoto, ... Nature communications 12 (1), 687, 2021 | 43 | 2021 |
| Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity WC Lee, A Reuben, X Hu, N McGranahan, R Chen, A Jalali, MV Negrao, ... Genome biology 21, 1-21, 2020 | 41 | 2020 |
| Expression of the SARS-CoV-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer H Zhang, K Quek, R Chen, J Chen, B Chen Journal of Cancer 11 (18), 5289, 2020 | 32 | 2020 |
| Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer M Chen, R Chen, Y Jin, J Li, X Hu, J Zhang, J Fujimoto, SM Hubert, ... Nature communications 12 (1), 6655, 2021 | 31 | 2021 |
| Hydrogel based 3D carriers in the application of stem cell therapy by direct injection C Luan, P Liu, R Chen, B Chen Nanotechnology Reviews 6 (5), 435-448, 2017 | 29 | 2017 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov … A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... CD-17-0256.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 28 | |
| Dynamics of serum tumor markers can serve as a prognostic biomarker for Chinese advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors Z Zhang, F Yuan, R Chen, Y Li, J Ma, X Yan, L Wang, F Zhang, H Tao, ... Frontiers in Immunology 11, 1173, 2020 | 27 | 2020 |
| Lobaplatin-induced apoptosis requires p53-mediated p38MAPK activation through ROS generation in non-small-cell lung cancer H Zhang, R Chen, X Wang, H Zhang, X Zhu, J Chen Frontiers in Oncology 9, 538, 2019 | 26 | 2019 |
Jianjun ZhangAssociate Professor, Dept. Thoracic/Head and Neck Medical Oncology, Dept. Genomic Medicine, MDVerified email at mdanderson.org
